Background glowZORYVE (roflumilast) topical foam, 0.3%

Actor portrayal

Background glowZORYVE (roflumilast) topical foam, 0.3%

Actor portrayal

 Itch Relief

SIGNIFICANT ITCH RELIEF IN STRATUM

RAPID ITCH RELIEF WITH A ONCE-DAILY, STEROID-FREE FOAM

Actor portrayal

63% OF PATIENTS ACHIEVED SIGNIFICANT ITCH
RELIEF AT WEEK 81,5*

(WI-NRS Success)

†P=0.0005.‡P=0.0003.§P<0.0001.ZORYVE (n=206)WEEK 2WEEK 4WEEK 8Vehicle (n=98) 100500PERCENTAGE OF PATIENTS48%‡16%33%†63%§29%41%
†P=0.0005.‡P=0.0003.§P<0.0001.0ZORYVE (n=206)Vehicle (n=98) (HYDROWEEK 2WEEK 4WEEK 8PERCENTAGE OF PATIENTS1008060402048%‡33%†63%§16%29%41%

DAILY WI-NRS

PATIENTS REPORTED GREATER IMPROVEMENT IN ITCH FROM BASELINE IN 2 DAYS COMPARED TO VEHICLE (28% vs 13%)6‖

*WI-NRS = Worst-Itch Numeric Rating Scale. WI-NRS Success was defined as a ≥4-point improvement for patients with a baseline score of ≥4. WI-NRS: 0 (no itch) to 10 (worst imaginable itch). 67% of participants reported a baseline WI-NRS ≥4.1,2

‖Least squares mean change from baseline of daily WI-NRS (nominal P=0.0024). N=457. Prespecified exploratory endpoint.

Review the Study Design
See Before & After Photos
View Safety Profile